AAIC 2026 opens Sunday July 12 in London; Gallup 11% GLP-1 usage / 36.4% obesity rate; Novartis-Myricx $1.5B ADC deal; Lonza-Nona BBB deal.
Read digest →MindRank $52M Series B for oral GLP-1 MDR-001; White House FDA commissioner review; WaPo peptide showdown; AZ/Ionis Wainua Phase 3 miss; China trial letters.
Read digest →PCAC written-comment member-review closes today; NPR feature on peptide push; Rhythm TRANSCEND setmelanotide in NEJM; HIMS analyst spread; oral GLP-1 tracker.
Read digest →Axios: Chinese fentanyl makers pivot to peptides; Kalohexis IPO on MC3R/MC4R obesity; FDA 23 novel approvals; Vera Trutakna approved; PCAC comment cutoff Jul 9.
Read digest →Vivani and Novo partner on a semaglutide implant, Kailera's oral GLP-1 clears Phase 3 in China, and a JAMA study finds online GLP-1 prescribing fast and loose.
Read digest →Jerome Adams pitches a regulated 503A middle path for peptides, Medicare GLP-1 Bridge denials trace to a billing code, and Lantheus draws an edotreotide CRL.
Read digest →KFF projects Bridge cost $1.3-10B; Sandoz generic tirzepatide ANDAs accepted; Knoepfler 'stacked' quote; BPC-157 pipeline retrospective ahead of PCAC.
Read digest →Novo Millar statement on Wegovy Bridge access; Pep Club telehealth launch; US News/AP FDA scientists warning; PolitiFact retatrutide primer; Bridge Day 2.
Read digest →Medicare GLP-1 Bridge launches at $50/month; 3.8M eligible per KFF; 4 questions linger per Becker's; Public Citizen and BioCentury oppose peptide deregulation.
Read digest →FDA scientists flag insufficient evidence on 7 peptides; STAT scoops PCAC panelist conflicts; oral testimony closes today; Medicare Bridge launches July 1.
Read digest →FDA 503B GLP-1 comments close today; Medicare Bridge media wave; PCAC testimony Tuesday; Zymeworks-Theravance $929M; pharmacist guidance; HIMS analyst notes.
Read digest →Sacred Eye Beauty 30-Day Ritual launches with GHK-Cu/PQQ/Methylene Blue; FDA 503B GLP-1 comment deadline June 29; regulatory week ahead Mon-Wed.
Read digest →STAT BIO 2026 wrap on AI + China; UVA Dr. Varney warns BPC-157/TB-500 evidence is animal-only; Medscape: retatrutide poison exposures up 265%.
Read digest →Sangamo Chapter 11 + Lilly $50M; 18 bioethics experts on retatrutide; ONVAX-01; HIMS rally; Medicare GLP-1 Bridge July 1; brain peptides Alzheimer's review.
Read digest →Hassan letter to RFK Jr on retatrutide compassionate use; Lilly's first statement; Lieu terminal-illness press conference; BIO 2026 wraps June 25.
Read digest →Lilly halves Alzey plant on German pricing reform; White House escalates retatrutide pushback; PCAC oral testimony deadline June 30; anti-Pseudomonas AMPs.
Read digest →STAT: FDA-Lilly retatrutide compassionate use for mystery 79-year-old; Elicio AMPLIFY-7P miss; Hims stock above $30 on PCAC; Medicare GLP-1 Bridge July 1.
Read digest →BIO 2026 Day 1 brings BioArctic-Lilly $800M BrainTransporter pact; Wegovy MASH approved in Japan; TGA peptide crackdown; USTR Germany 301; AGA POWER revision.
Read digest →